Unlike patients with lung cancer, whose smoking status is associated with specific mutations (such as high levels of C > A nucleotide transversions and KRAS mutations), the mutation burden is similar in bladder tumors of nonsmokers and current smokers, and there is a lack of an association between the smoking status and the mutational spectrum [35,36,37]. The gene discussed is KRAS; the disease is urinary bladder neoplasm.